Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Nimeiri, HS
  • Oza, AM
  • Morgan, RJ
  • Huo, D
  • Elit, Laurie
  • Knost, J
  • Wade, JL
  • Agamah, E
  • Vokes, EE
  • Fleming, GF

publication date

  • May 20, 2008